Q1 Earnings Estimate for Altimmune Issued By B. Riley

Altimmune, Inc. (NASDAQ:ALT) – Investment analysts at B. Riley issued their Q1 2025 earnings estimates for shares of Altimmune in a research note issued to investors on Wednesday, November 13th. B. Riley analyst M. Mamtani anticipates that the company will post earnings per share of ($0.41) for the quarter. B. Riley currently has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Altimmune’s current full-year earnings is ($0.54) per share. B. Riley also issued estimates for Altimmune’s FY2025 earnings at $0.73 EPS.

Other research analysts have also recently issued reports about the company. UBS Group assumed coverage on Altimmune in a research note on Tuesday. They issued a “buy” rating and a $26.00 price objective for the company. Evercore ISI upgraded shares of Altimmune to a “strong-buy” rating in a report on Friday, August 9th. Finally, HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Altimmune in a research note on Thursday. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Altimmune presently has an average rating of “Moderate Buy” and an average price target of $20.00.

Altimmune Price Performance

Shares of ALT stock opened at $7.61 on Thursday. The business has a fifty day moving average of $7.02 and a 200 day moving average of $6.91. The firm has a market capitalization of $541.22 million, a price-to-earnings ratio of -4.91 and a beta of 0.09. Altimmune has a 1 year low of $2.34 and a 1 year high of $14.84.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.03. The business had revenue of $0.01 million during the quarter. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same quarter in the previous year, the firm posted ($0.39) earnings per share.

Insider Buying and Selling at Altimmune

In other Altimmune news, Director David Drutz sold 16,011 shares of the company’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $6.90, for a total value of $110,475.90. Following the completion of the transaction, the director now owns 41,958 shares in the company, valued at approximately $289,510.20. This represents a 27.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 4.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Altimmune

Several institutional investors and hedge funds have recently modified their holdings of ALT. CANADA LIFE ASSURANCE Co purchased a new stake in Altimmune in the 1st quarter worth $44,000. Larson Financial Group LLC purchased a new stake in shares of Altimmune during the third quarter worth about $31,000. TFO Wealth Partners LLC acquired a new position in shares of Altimmune during the 1st quarter worth about $51,000. Horizon Wealth Management LLC purchased a new position in Altimmune in the 2nd quarter valued at about $66,000. Finally, PFG Investments LLC acquired a new stake in Altimmune in the 2nd quarter worth about $67,000. Hedge funds and other institutional investors own 78.05% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.